Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 2:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 15,129 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Randomized Controlled Study Clear all
Recruiting Phase 3 Interventional

A Study to Compare the Efficacy and Safety of TachoSil and Surgicel Original as an Adjunct to Control Mild to Moderate Soft Tissue Bleeding During Surgery

NCT06664775
View directory record Official record
Conditions
Hemorrhage
Interventions
TachoSil, Surgicel Original
Biological
Lead sponsor
Corza Medical GmbH
Industry
Eligibility
1 Month and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
9
States / cities
Torrance, California • Lakewood, Colorado • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 24, 2026, 2:38 AM EDT
Completed Not applicable Interventional

A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (HOPE Study)

NCT05637801
View directory record Official record
Conditions
Alzheimer Disease, Alzheimer Disease 1, Alzheimer Disease 2, Alzheimer Disease 3, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Alzheimer Disease 9, Alzheimer Disease 4, Alzheimer Disease 7, Alzheimer Disease 17, Alzheimer's Dementia Late Onset, Alzheimer Disease 5, Alzheimer Disease 6, Alzheimer Disease 8, Alzheimer Disease 10, Alzheimer Disease 11, Alzheimer Disease 12, Alzheimer Disease 13, Alzheimer Disease 14, Alzheimer Disease 15, Alzheimer Disease 16, Alzheimer Disease 18, Alzheimer Disease 19, Dementia, Dementia Alzheimers, Dementia, Mild, Dementia of Alzheimer Type, Dementia Moderate, Dementia Senile, Mild Cognitive Impairment, Mild Dementia, MCI, Cognitive Impairment, Cognitive Decline, Cognitive Impairment, Mild
Interventions
Spectris™ AD - Active, Spectris™ AD - Sham
Device
Lead sponsor
Cognito Therapeutics, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
673 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
68
States / cities
Gilbert, Arizona • Phoenix, Arizona • Sun City, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 24, 2026, 2:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Cardiac Safety of Oritavancin in Healthy Participants

NCT01762839
View directory record Official record
Conditions
Healthy
Interventions
Single-Dose IV Oritavancin Diphosphate, Placebo, Moxifloxacin
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Oct 24, 2026, 2:38 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Efficient Study of ACULAR in Inhibiting Proliferative Retinopathy in Prematurity

NCT00634972
View directory record Official record
Conditions
Retinopathy of Prematurity, Retinal Detachment, Blindness
Interventions
ACULAR, REFRESH TEARS, placebo
Drug
Lead sponsor
University of South Alabama
Other
Eligibility
10 Days to 15 Days
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Mobile, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Oct 24, 2026, 2:38 AM EDT
Active, not recruiting Phase 3 Interventional

Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa

NCT06079372
View directory record Official record
Conditions
Hypophosphatasia
Interventions
ALXN1850, asfotase alfa
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
2 Years to 11 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
6
States / cities
Hartford, Connecticut • Baltimore, Maryland • Minneapolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 24, 2026, 2:38 AM EDT
Terminated Phase 2 Interventional

Investigation of Neural Stem Cells in Ischemic Stroke

NCT03629275
View directory record Official record
Conditions
Ischemic Stroke, Chronic Stroke, Hemiparesis, Arm Paralysis
Interventions
CTX0E03 Drug Product and delivery device, Placebo
Combination Product · Drug
Lead sponsor
ReNeuron Limited
Industry
Eligibility
35 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
23
States / cities
Little Rock, Arkansas • Irvine, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2021 · Synced Oct 24, 2026, 2:38 AM EDT
Completed Phase 2 Interventional Results available

A Study of RO4607381 in Patients With Coronary Heart Disease (CHD) or a CHD Risk Equivalent.

NCT00353522
View directory record Official record
Conditions
Coronary Heart Disease
Interventions
Placebo, dalcetrapib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
10
States / cities
Chicago, Illinois • Indianapolis, Indiana • Iowa City, Iowa + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Oct 24, 2026, 2:38 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of AeroVanc for the Treatment of Persistent MRSA Lung Infection in Cystic Fibrosis Patients

NCT01746095
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Vancomycin hydrochloride inhalation powder, Placebo inhalation powder
Drug
Lead sponsor
Savara Inc.
Industry
Eligibility
12 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
38
States / cities
Mobile, Alabama • Little Rock, Arkansas • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 24, 2026, 2:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety and Tolerability, and Pharmacokinetics of UCB0022 in Healthy Caucasian, Japanese, and Chinese Participants

NCT06970301
View directory record Official record
Conditions
Healthy Study Participants
Interventions
glovadalen, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 24, 2026, 2:38 AM EDT
Terminated Phase 2 Interventional

Safety and Efficacy Study to Evaluate the Effect of SLV320 on Renal Function in Patients With Worsening Heart Failure

NCT00744341
View directory record Official record
Conditions
Acute Decompensated Heart Failure; Renal Dysfunction
Interventions
SLV320, Placebo
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
28
States / cities
Alameda, California • Banning, California • Inglewood, California + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2010 · Synced Oct 24, 2026, 2:38 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis

NCT01900431
View directory record Official record
Conditions
Uveitis
Interventions
Sarilumab, Prednisone, Methotrexate, Folic/folinic acid, Placebo (for Sarilumab)
Drug · Other
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
5
States / cities
Worcester, Massachusetts • Omaha, Nebraska • Slingerlands, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Oct 24, 2026, 2:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C.

NCT06742853
View directory record Official record
Conditions
Dyslipidemia
Interventions
AZD0780, Ezetimibe, Rosuvastatin, Bempedoic Acid, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Glendale, California • Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 24, 2026, 2:38 AM EDT
Terminated Phase 3 Interventional Results available

Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS

NCT06524739
View directory record Official record
Conditions
Post-COVID Postural Orthostatic Tachycardia Syndrome
Interventions
IgPro20, Placebo
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
34
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 24, 2026, 2:38 AM EDT
Completed Phase 4 Interventional Results available

Study of Exparel Versus Epidural for Pain Control After Thoracotomy

NCT02178553
View directory record Official record
Conditions
Pain Following Thoracotomy Surgery
Interventions
Epidural, Intercostal Bupivicaine (Exparel)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 9, 2020 · Synced Oct 24, 2026, 2:38 AM EDT
Completed Not applicable Interventional

Omega-3 Fatty Acids in Preventing Joint Symptoms in Patients With Stage I-III Breast Cancer Receiving Anastrozole, Exemestane, or Letrozole

NCT01478477
View directory record Official record
Conditions
Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
omega-3 fatty acid supplement, Placebo, Clinical assessments, Assessment of therapy complications, Magnetic Resonance Imaging, Correlative/special studies
Dietary Supplement · Other · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Oct 24, 2026, 2:38 AM EDT
Completed Phase 2 Interventional Results available

A 12-week Study To Evaluate PF-06291874 Once a Day in Adults With T2DM Inadequately Controlled On Metformin

NCT02554877
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
PF-06291874, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
32
States / cities
Anaheim, California • Los Angeles, California • Orange, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2017 · Synced Oct 24, 2026, 2:38 AM EDT
Completed Phase 3 Interventional Results available

A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-03)

NCT02943577
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Rapastinel, Placebo
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
18 Years to 65 Years
Enrollment
429 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
40
States / cities
Dothan, Alabama • Phoenix, Arizona • Imperial, California + 34 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Oct 24, 2026, 2:38 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A First in Human, Dose Escalation Study to Evaluate the Safety and Tolerability of BBP-671 in Healthy Volunteers and Patients With Propionic Acidemia or Methylmalonic Acidemia

NCT04836494
View directory record Official record
Conditions
Healthy Volunteers, Propionic Acidemia, Methylmalonic Acidemia, Organic Acidemia
Interventions
BBP-671, Placebo
Drug
Lead sponsor
CoA Therapeutics, Inc., a BridgeBio company
Industry
Eligibility
15 Years to 55 Years
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
3
States / cities
Topeka, Indiana • Pittsburgh, Pennsylvania • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 24, 2026, 2:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Assess the Pharmacokinetics and Safety of Single Doses of JNJ-54452840 in Healthy Japanese and Caucasian Participants

NCT01809353
View directory record Official record
Conditions
Healthy
Interventions
JNJ-54452840, Placebo
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
20 Years to 55 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Mar 23, 2015 · Synced Oct 24, 2026, 2:38 AM EDT
Completed Phase 2 Interventional Results available

Study of GSK1278863 to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair

NCT01920594
View directory record Official record
Conditions
Surgical Procedures
Interventions
GSK1278863, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
13
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2017 · Synced Oct 24, 2026, 2:38 AM EDT
Completed Phase 3 Interventional Results available

Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma

NCT00529529
View directory record Official record
Conditions
Asthma
Interventions
Indacaterol 300 μg, Salmeterol 50 μg, Placebo to indacaterol, Placebo to salmeterol
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
805 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
56
States / cities
Glendale, Arizona • Phoenix, Arizona • Encinitas, California + 44 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2011 · Synced Oct 24, 2026, 2:38 AM EDT
Terminated Phase 4 Interventional

A Study to Evaluate the Use of Extended Release Alprazolam in the Treatment of Adolescents With Panic Disorder

NCT00635531
View directory record Official record
Conditions
Panic Disorder
Interventions
placebo, alprazolam XR
Other · Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
13 Years to 17 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
18
States / cities
Hialeah, Florida • Jacksonville, Florida • North Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Oct 24, 2026, 2:38 AM EDT
Completed Phase 1 Interventional

Study of PIPE-791 for Subjects With Chronic Osteoarthritis Pain or Chronic Low Back Pain

NCT06810245
View directory record Official record
Conditions
Chronic Osteoarthritis Pain, Chronic Low Back Pain
Interventions
PIPE-791, Placebo
Drug
Lead sponsor
Contineum Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Phoenix, Arizona • Marietta, Georgia • Hartsdale, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 24, 2026, 2:38 AM EDT
Completed Phase 1Phase 2 Interventional Results available

TJ-68 Clinical Trial in Patients With Amyotrophic Lateral Sclerosis (ALS) and Muscle Cramps

NCT04998305
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Muscle Cramp
Interventions
TJ-68, Placebo
Drug
Lead sponsor
Hiroshi Mitsumoto
Other
Eligibility
20 Years to 84 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Oct 24, 2026, 2:38 AM EDT